Stay updated with breaking news from Eli Lilly S. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Unravel the competition for Ozempic with Eli Lilly's Zepbound, an FDA-approved breakthrough in weight loss—a revolutionary obesity treatment that promises a 52-pound shred in 16 months.
What the soda and snack maker says about weight-loss drugs could be just as important as its profits.
RBC Capital Markets analyst Nik Modi initiated coverage of Utz stock with an Outperform rating and $17 price target.
RBC Capital Markets analyst Nik Modi initiated coverage of Utz stock with an Outperform rating and $17 price target.